How do we safely get people to stop smoking?

David C L Lam, John D. Minna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nicotine replacement therapy (NRT) is a valuable, proven, and U.S. Food and Drug Administration-approved tool for smoking cessation. However, the discoveries of functional nicotinic acetylcholine receptors (nAChR) on lung epithelial and cancer cells and of nAChR polymorphisms associated with lung cancer risk, in addition to a large number of preclinical studies indicating that nicotine may promote or facilitate cancer development and growth, have prompted concern that NRT, although important for smoking cessation, may actually augment lung carcinogenesis. Therefore, it is of great public health interest that two independent studies reported in this issue of the journal (Murphy and colleagues, beginning on page 1752, and Maier and colleagues, beginning on page 1743) showed that nicotine given in drinking water at a dose to achieve blood concentrations in mice similar to those achieved in people receiving NRT did not enhance lung carcinogenesis or tumor growth in several mouse models of lung cancer. Effective nonnicotine alternatives to NRT, such as varenicline and bupropion, are also available and perhaps better than NRT for smoking cessation therapy. In the near future, nicotine vaccines will likely be added to the smoking cessation armamentarium. However, the normal and pathophysiologic role of nicotine, nAChRs, and the signaling pathways they activate in lung epithelial cells and lung cancer still requires elucidation.

Original languageEnglish (US)
Pages (from-to)1724-1727
Number of pages4
JournalCancer Prevention Research
Volume4
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Nicotine
Smoking
Smoking Cessation
Lung Neoplasms
Nicotinic Receptors
Lung
Carcinogenesis
Therapeutics
Epithelial Cells
Bupropion
United States Food and Drug Administration
Growth and Development
Drinking Water
Neoplasms
Vaccines
Public Health
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

How do we safely get people to stop smoking? / Lam, David C L; Minna, John D.

In: Cancer Prevention Research, Vol. 4, No. 11, 11.2011, p. 1724-1727.

Research output: Contribution to journalArticle

Lam, David C L ; Minna, John D. / How do we safely get people to stop smoking?. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 11. pp. 1724-1727.
@article{6d524dcbc80a4041b8f370a65e52a95b,
title = "How do we safely get people to stop smoking?",
abstract = "Nicotine replacement therapy (NRT) is a valuable, proven, and U.S. Food and Drug Administration-approved tool for smoking cessation. However, the discoveries of functional nicotinic acetylcholine receptors (nAChR) on lung epithelial and cancer cells and of nAChR polymorphisms associated with lung cancer risk, in addition to a large number of preclinical studies indicating that nicotine may promote or facilitate cancer development and growth, have prompted concern that NRT, although important for smoking cessation, may actually augment lung carcinogenesis. Therefore, it is of great public health interest that two independent studies reported in this issue of the journal (Murphy and colleagues, beginning on page 1752, and Maier and colleagues, beginning on page 1743) showed that nicotine given in drinking water at a dose to achieve blood concentrations in mice similar to those achieved in people receiving NRT did not enhance lung carcinogenesis or tumor growth in several mouse models of lung cancer. Effective nonnicotine alternatives to NRT, such as varenicline and bupropion, are also available and perhaps better than NRT for smoking cessation therapy. In the near future, nicotine vaccines will likely be added to the smoking cessation armamentarium. However, the normal and pathophysiologic role of nicotine, nAChRs, and the signaling pathways they activate in lung epithelial cells and lung cancer still requires elucidation.",
author = "Lam, {David C L} and Minna, {John D.}",
year = "2011",
month = "11",
doi = "10.1158/1940-6207.CAPR-11-0449",
language = "English (US)",
volume = "4",
pages = "1724--1727",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - How do we safely get people to stop smoking?

AU - Lam, David C L

AU - Minna, John D.

PY - 2011/11

Y1 - 2011/11

N2 - Nicotine replacement therapy (NRT) is a valuable, proven, and U.S. Food and Drug Administration-approved tool for smoking cessation. However, the discoveries of functional nicotinic acetylcholine receptors (nAChR) on lung epithelial and cancer cells and of nAChR polymorphisms associated with lung cancer risk, in addition to a large number of preclinical studies indicating that nicotine may promote or facilitate cancer development and growth, have prompted concern that NRT, although important for smoking cessation, may actually augment lung carcinogenesis. Therefore, it is of great public health interest that two independent studies reported in this issue of the journal (Murphy and colleagues, beginning on page 1752, and Maier and colleagues, beginning on page 1743) showed that nicotine given in drinking water at a dose to achieve blood concentrations in mice similar to those achieved in people receiving NRT did not enhance lung carcinogenesis or tumor growth in several mouse models of lung cancer. Effective nonnicotine alternatives to NRT, such as varenicline and bupropion, are also available and perhaps better than NRT for smoking cessation therapy. In the near future, nicotine vaccines will likely be added to the smoking cessation armamentarium. However, the normal and pathophysiologic role of nicotine, nAChRs, and the signaling pathways they activate in lung epithelial cells and lung cancer still requires elucidation.

AB - Nicotine replacement therapy (NRT) is a valuable, proven, and U.S. Food and Drug Administration-approved tool for smoking cessation. However, the discoveries of functional nicotinic acetylcholine receptors (nAChR) on lung epithelial and cancer cells and of nAChR polymorphisms associated with lung cancer risk, in addition to a large number of preclinical studies indicating that nicotine may promote or facilitate cancer development and growth, have prompted concern that NRT, although important for smoking cessation, may actually augment lung carcinogenesis. Therefore, it is of great public health interest that two independent studies reported in this issue of the journal (Murphy and colleagues, beginning on page 1752, and Maier and colleagues, beginning on page 1743) showed that nicotine given in drinking water at a dose to achieve blood concentrations in mice similar to those achieved in people receiving NRT did not enhance lung carcinogenesis or tumor growth in several mouse models of lung cancer. Effective nonnicotine alternatives to NRT, such as varenicline and bupropion, are also available and perhaps better than NRT for smoking cessation therapy. In the near future, nicotine vaccines will likely be added to the smoking cessation armamentarium. However, the normal and pathophysiologic role of nicotine, nAChRs, and the signaling pathways they activate in lung epithelial cells and lung cancer still requires elucidation.

UR - http://www.scopus.com/inward/record.url?scp=81555195424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81555195424&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-11-0449

DO - 10.1158/1940-6207.CAPR-11-0449

M3 - Article

VL - 4

SP - 1724

EP - 1727

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 11

ER -